Skip to content
Screener

Ocular Therapeutix OCUL Q2 2026 earnings

Reported August 3, 2026 · Before market open

Revenue$13.5MBeat by $273.6K
EPS-$0.35Beat by $0.05
Revenue estimate$13.2M
EPS estimate-$0.40
“This approach is designed to support the fastest risk-mitigated path to NDA submission and review. Consistent with the FDA Type C meeting minutes, the AXPAXLI NDA submission will be based on SOL-1 efficacy and safety data, interim safety data from SOL-R and supporting confirmatory evidence, including axitinib's established profile as a VEGFR inhibitor from more than a decade of clinical use since FDA approval for renal cell carcinoma. By pursuing the 505(b)(2) regulatory pathway, we believe the AXPAXLI NDA submission is strongly positioned to benefit from a review timeline up to 60 days shorter than the typical new molecular entity.”
Pravin U. Dugel

Next report

Nov 3, 2026 (Tomorrow)
Revenue estimate$14.3M
EPS estimate-$0.36

Financials

Q2 2026

Income statement

See full
Revenue$13.5M+0.1%
Gross profit$11.5M-0.4%
Operating income-$82.1M-21.4%
Net income-$78.8M-16.1%
EPS (diluted)-$0.35+10.3%

Balance sheet

See full
Cash & equivalents$598.6M+53.1%
Total debt$79.4M+3.2%
Total equity$520.0M+70.0%
Total assets$671.3M+48.7%

Cash flow

See full
Operating cash flow-$67.3M-21.8%
CapEx$3.4M+170%
Free cash flow-$70.6M-25.1%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$1.61B-35.9%
Enterprise value$1.09B-51.4%
P/S30.8×-14.1×

Profitability

See full
Gross margin87.1%-2.3pp
Operating margin-603%+598pp
Net margin-579.1%+612pp
FCF margin-490.1%+595pp

Returns & leverage

See full
Return on equity-73%+13.0pp
Debt / equity0.2×-0.1×
Current ratio13.1×+3.0×

Segments

By segment

See full
Single Reportable$13.5M+0.1%

FAQ

When did Ocular Therapeutix report Q2 2026 earnings?
Ocular Therapeutix (OCUL) reported Q2 2026 earnings on August 3, 2026 before market open.
What were Ocular Therapeutix's Q2 2026 revenue and EPS?
Ocular Therapeutix reported revenue of $13.5M and eps of $-0.35 for Q2 2026.
Did Ocular Therapeutix beat estimates in Q2 2026?
Revenue beat the consensus estimate of $13.2M by $273.6K. EPS beat the consensus estimate of $-0.40 by $0.05.
How did Ocular Therapeutix's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 0.1% from $13.5M a year earlier and eps grew 10.3% from $-0.39.
Where can I find Ocular Therapeutix's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-089443) and the 10-Q periodic report (0001104659-26-089450) directly on SEC EDGAR. The filing index links above go to sec.gov.